Introducing Dacomitinib (Daconib 45 mg), a trailblazing non-small cell lung cancer (NSCLC) solution from Everest Pharmaceuticals Ltd. Daconib 45 mg is the most powerful NSCLC treatment available, with results that far exceed traditional treatments. It has been clinically proven to reduce tumour size, improve overall survival, and increase quality of life. It is a revolutionary new treatment for NSCLC. Specially designed for patients with metastatic NSCLC, notably with EGFR exon 19 deletion or exon 21 L858R substitution mutations, this irreversible kinase inhibitor impedes the EGFR family’s growth and mutation activities, making it a first-line treatment option for NSCLC.
Clinical trials have found that this new treatment can block the activity of a group of proteins known as tyrosine kinases. These proteins are responsible for the growth and spread of cancer cells. This means that it can stop the progression of cancer, reduce the size of tumours, and improve the overall quality of life of patients. Dacomitinib inhibits the activity of EGFR, HER1, HER2, and HER4. It also suppresses DDR1, EPHA6, LCK, DDR2, and MNK1, contributing to its clinically-proven effectiveness. In lab experiments, it inhibited EGFR and HER2 autophosphorylation dose-dependently, inhibiting tumour growth. Moreover, Dacomitinib exhibits anti-tumour activity in orally-dosed lab animals bearing intracranial human tumour xenografts driven by EGFR amplification.
Administered orally once a day, Dacomitinib (Daconib 45 mg) is easy to incorporate into your daily routine. It can be taken with or without food but should be consumed at the same time each day for optimal results. Its dosage doesn’t require adjustment for mild or moderate hepatic or renal impairments. However, consult a healthcare professional for severe conditions.
While Dacomitinib has potential side effects like diarrhoea, rash, paronychia, and stomatitis, these are typically manageable. More serious side effects such as ILD/pneumonitis and severe diarrhoea are less common and should be immediately addressed by a healthcare professional.
Pregnant women or women of reproductive potential should exercise extra caution when using Dacomitinib, and breastfeeding is not recommended during treatment.
Choose Everest Pharmaceuticals’ Dacomitinib (Daconib 45 mg) for a practical and innovative approach to NSCLC treatment. As a testament to our commitment to advancing healthcare and delivering quality medicines, Everest Pharmaceuticals is your trusted partner in the fight against non-small cell lung cancer. Join the thousands of patients who benefit from Dacomitinib today.
